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doi:10.1016/j.pcad.2006.03.001Essential hypertension has rather recently become
recognized as a major factor in the development of
the 2 main types of dementia, that is, no longer
merely vascular dementia but Alzheimer disease as
well. The relationship between high blood pressure
(BP) and the dementias is quite a complicated one,
given a wide variability in temporal courses. The
interval between the respective manifestations of
hypertension and cognitive deterioration may vary
from a few years to several decades. Moreover,
temporal relationships may be obscured because of
the observation that BP tends to fall in the face of
imminent Alzheimer disease. Although the cause-
and-effect sequence of this relationship has not
been established, it may suggest that a low BP in
this phase of life could be equally harmful as
hypertension in the preceding period. Individual
monitoring of BP and drug titration in the hyperten-
sive elderly may well become mandatory in the
highest age group. The question whether some
antihypertensive drug categories might act more
effectively in preventing cognitive deterioration than
others, irrespective of their antihypertensive poten-
tial, remains. A modest meta-analysis on our part
seems to suggest that suppression of the renin-
angiotensin-aldosterone system (RAAS) would fail
to offer such protection, in contrast to certain
dihydropyridine (DHP) calcium-channel blockers.
Unfortunately, recently published comparative pro-
spective megatrials (Anti-hypertensive and Lipid-
lowering Treatment to Prevent Heart Attack Trial
and Anglo-Scandinavian Cardiac Outcomes Trial–
Blood Pressure Lowering Arm) failed to carry any
record on the mental status of the study popula-
tions, thereby missing a golden opportunity to
resolve the above issue. Consequently, there
remains an urgent need for further blinded long-
term comparative hypertension trials, including
follow-up evaluation of cognitive functions in rela-
tion to the course of BP.
n 2006 Elsevier Inc. All rights reserved.
Cognitive deterioration and its end pointovert dementia are, in brief, to be charac-
terized by progressive memory loss, disorienta-Progress in Cardiovascular Diseases, Vol. 49, No. 1 (July/Augution in time and space, loss of autonomy, and
ultimately, depersonalisation/alienation.
The dementia syndrome by tradition used to
be specified into 2 main prototypes: degenera-
tive dementia or Alzheimer disease vs vascular
dementia. Despite a vast and ongoing literature
on differential features between the 2 forms, the
overriding importance of such discriminating
characteristics is now moving to the background
in the face of epidemiologically oriented re-
search. As Hofman et al1 in Rotterdam have
shown, the 2 subtypes share atherosclerosis as a
major background factor, partly dependent on
the presence or absence of the apolipoprotein E
genotype. The atherosclerotic component of
Alzheimer disease has also been stressed by
Casserly and Topol.2
From another angle, a collaborative neuropath-
ological study under the auspices of the Medical
Research Council (UK) confirmed a considerable
overlap between the microscopic substrates of
degenerative and vascular dementia.3Epidemiology of Dementias at Large
Traditionally, both subtypes of dementia are
associated with the aging process and, hence,
increase pari passu with the longevity of human-
kind, as estimated in the Europe and the United
States. In the western world, some 10 years ago,
the prevalence of memory impairment in thest), 2006: pp 1-10 1




! Apolipoprotein E4 allele
! Sex (female N male)
! Vascular risk factors and damage (hypertension, diabe-
tes, and stroke)
! Depression
! Poor educational level
! Sedentary lifestyle
! Social disengagement
BIRKENHA¨GER AND STAESSEN2older population was already estimated to be
17% to 34%,4 - 7 and overt dementia (80% of the
Alzheimer type) affected 3.6% to 10.3% of the
population older than 65 years.8,9
It is estimated that the incidence of dementia
exponentially increases with age with rates of
5 to 10 cases per 1000 person-years at 70 years
and older to 20 to 40 cases per 1000 person-
years at 80 years.10 Hence, given the current
worldwide demographical transition from high
to low rates of birth and death, dementia is
bound to grow into one of the principal causes
of disability and reduced general quality of life
in the community at large.
A major concern is that medical treatment of
established dementia, so far, has shown only
marginal benefit, without any promise of cost-
effectiveness.11,12
This reinforces the need for focusing on the
possibility of prophylactic measures to be derived
from potential cofactors involved in the patho-
genesis of degenerative and vascular dementias.
Unfortunately most of those are hardly, if at all,
amenable to social or medical interference
(Table 1). It appears that the major preventable
factor is liaised with hypertension and its sequelae
or associated metabolic derangements.Hypertension and Dementia
Although hypertension has long been recog-
nized to play a role in the pathogenesis of
vascular dementia, its identification as an
equipotent risk factor in Alzheimer disease had
to await the final decade of the past century.
This has mainly been due to the lengthy lag
phase between the clinical diagnoses of hyper-
tension and cognitive deterioration, thus pre-
venting consistent correlations between the 2 on
a cross-sectional (contemporary) basis. The
moot results of such comparisons have been
extensively reported elsewhere.13,14 The extent
of the apparent phase difference between the 2
conditions is due to the insidious nature of
hypertensive target organ damage. For decades,
histologic lesions, such as neurofibrillary tangles
or an accelerated rate of neuronal atrophy in the
medial temporal lobe of the brain,15,16 may
precede overt dementia.
Because cross-sectional studies obviously lack
the potency to disclose an ad hoc intimaterelationship between blood pressure (BP) and
cognitive deterioration, longitudinal studies
were required to provide proper evidence pro
or contra a causative long-term relationship.
Overall, such follow-up studies have revealed
a high BP to be a graded and continuous risk
factor in the pathogenesis of both vascular and
degenerative dementias in the course of the
decade(s) after midlife.
In the Framingham study,16 BP levels of
participants 55 to 88 years of age were followed
up and averaged more than 5 biennial examina-
tions in an era (1956-1964) when most hyper-
tensive patients stayed untreated. In the period
1976 to 1978, in 1038 untreated survivors, the
composite cognitive score with separate mea-
sures of attention and memory appeared to be
inversely correlated with systolic and diastolic
BP at baseline.17
The substance of this finding was confirmed in
2 studies from Sweden, Gothenburgh18 and
Uppsala,19 and by the Honolulu-Asia Study,20
with follow-up periods of 15, 20, and 25 years,
respectively.
Although the above studies basically estab-
lished a positive relation between baseline BP
starting at any age and the risk of cognitive
impairment and overt dementia in the subse-
quent age range, this turned out to be less clear in
subjects receiving antihypertensive treatment in
the interim,19 as could be expected.
A variant course of late-life events was
discovered by Skoog et al18 in their meticulous
follow-up of hypertensive patients 70 years and
older. They examined the relationship between
BP and dementia starting with nondemented
patients at 70 years of age and following them up
PROGRESS IN CARDIOVASCULAR DISEASE 3at 5-year intervals up to 85 years of age. In this
observation period, patients prone to developing
degenerative dementia later on had higher
systolic and diastolic BPs than the others but
paradoxically exhibited a fall in BP in the years
before the onset of dementia. White matter
lesions on magnetic resonance imaging appeared
to predispose to this phenomenon.18
This paradoxical decline in BP in patients at
increased risk of dementia is still to be
explained. Physical inactivity in those blemished
by advancing mental deterioration may be a
substantial factor. Skoog21 proposed another
hypothesis in that failure to maintain usual BP
at this stage might well be an expression of
Alzheimer-type lesions in prefrontal autonomic
ganglia resulting in central dysregulation of BP
control. Orthostatic or postprandial dips in BP,
pari passu with episodes of impaired cerebro-
vascular blood flow, might indeed contribute to
further cerebrocellular damage.22
Whatever the mechanism of this rather omi-
nous BP decline, in practice, it should require
careful titration/adjustment of ongoing antihy-
pertensive medication in the very elderly. The
latter aspect will be discussed later on.
At the early part of the age spectrum, a recent
observation revealed a comparable seemingly
paradoxical development. Although it has been
commonly accepted that the incidence of de-
mentia exponentially increases with age with
rates from 5 to 10 cases per 1000 person-years at
70 years and older to 20 to 40 cases at 80
years,10 it now seems that recognition of
cognitive decline should no longer be limited
to hypertension in the elderly. In the Maine-
Syracuse Longitudinal Study of Hypertension,
Elias et al23 followed up subjects in 2 age groups
(18-46 and 47-83 years) for (potentially) up to
20 years. In a sophisticated 2-step growth curve
analysis, baseline BPs, categorized according to
the seventh report of the Joint National Com-
mittee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure24 and
various cognitive performance ratings, were
evaluated in both age groups. It appeared that
the young (in a decline in visualization/fluid
abilities) were equally vulnerable in relation to
BP increments as their older counterpart. This
finding should serve as, perhaps, an even
stronger stimulus to contain hypertension in itsearly stage than the avoidance of more distant
mental sequelae.
Role of White Matter Lesions
White matter lesions on computed tomography or
magnetic resonance imaging are bendemicQ
among the elderly.25 Still, their absence or
presence may be clinically important, as already
alluded to above in the study by Skoog et al.18 The
analysis/calibration of white matter lesions, par-
ticularly regarding cognitive impairment in vas-
cular cerebral disorders, is being developed into a
refined art,26 which may, in due time, hopefully
be correlated with psychometric findings.
The role of hypertension in generating pro-
gressive white matter lesions, which correspond
to ischemic destruction of deep neuronal axons,
often with advanced microangiopathy (leading to
focal infarcts as forerunners to stroke and/or
neurodegenerative disorders), has long been
ignored. This episode of ignorance/neglect has
come to an end by virtue of a range of prospective
cohort studies wherein measurement of BP at
entry antedated magnetic resonance brain imag-
ing by 5 to 20 years and was repeated at the time of
the scans.
After adjustment for eventual confounders, the
prevalence and incidence of white matter lesions
augmented with high BP.27,28 This pattern was
subsequently roughly confirmed by the Cardio-
vascular Determinants of Dementia Study (CAS-
CADE) Consortium in which the above
investigators closed ranks with those from 7 other
European countries.29 The association between
white matter lesions and BP was particularly
strong in subjects with uncontrolled hyperten-
sion. It was graded and continuous for systolic
pressure but J-shaped for diastolic pressure. The
consortium speculated about various explana-
tions that might underlie the latter aberrant
relationship, but in our view, they missed the
most obvious angle.29 With aging, systolic BP
tends to become the major cardiovascular risk
factor. On the contrary, a decline in diastolic BP,
in the same late course of aging reflects the same
arteriosclerotic process as a marker of loss of
arterial compliance in its own right. As a matter of
fact, the cardiovascular risk of an increasing
systolic BP in the elderly has been shown to be
proportionally reinforced by the presence of
progressively reduced diastolic pressures.30
BIRKENHA¨GER AND STAESSEN4Observational Studies on the Effects
of Antihypertensive Treatment on
Cognitive Decline
Given the successful effects of antihypertensive
medication in containing stroke rates in elderly
hypertensive patients,31- 36 one could reasonably
hope for analogous effects regarding the preven-
tion of cognitive decline by protecting against
cerebral microvascular damage as one of the
substrate constituents of vascular—as well as
degenerative—dementia.
A range of observational studies relating
hypertension with cognitive malfunctioning in-
corporated the influence of concurrent antihy-
pertensive medications.
In the Kungsholmen Project from Sweden31
1301 hypertensive patients 75 years and older
were followed up for an average of 3 years.
Cognitive functions were assessed using the
Mini-Mental State Examination (MMSE) as well
as additional psychometric criteria. At the end of
the follow-up period, 987 subjects were still
alive. In a subpopulation with a systolic BP
higher than 160 mm Hg, a diastolc BP higher
than 95 mm Hg, or both, 122 had received
diuretic treatment. Compared with untreated
subjects, the patients, thus treated, showed an
adjusted relative risk for developing dementia of
0.6 (95% confidence interval [CI], 0.3-1.2). The
authors felt that this outcome might indicate a
potential benefit from diuretic treatment, al-
though they recognized the flaws of this study
in that the information on treatment was merely
available at baseline; moreover, confounding by
indication may well have biased the results.
In a further follow-up phase of the Kungshol-
men project,32 it was observed that a very low
diastolic BP (b65 vs 66-90 mm Hg) was associated
with an increased risk for dementia, particularly
in patients on antihypertensive treatment. Con-
versely, a high systolic BP (N180 mm Hg) carried a
similar risk, whereas low systolic pressures (140
mm Hg) appeared to be quite harmless. Appar-
ently, a further accumulation and integration of
BP data will be needed to arrive at a consensus for
optimal BP titration for cognitive preservation.
In the Epidemiology of Vascular Aging study,33
1389 subjects 59 to 74 years of age, were
recruited, including 167 hypertensive patients
who were re-examined 2 and 4 years later. After4 years, 81 hypertensive individuals had received
antihypertensive treatment with various drugs
(b-blockers, calcium-channel blockers [CCBs],
angiotensin-converting enzyme (ACE) inhibitors,
and diuretics). In untreated hypertensive
patients, a correlation was observed between the
level of BP and a subsequent decline in cognitive
function (a decrement of N4 points on the
30-point MMSE scale). The relative risk
amounted to 4.3 (95% CI, 2.3-8.0) as compared
with normotensive patients. By contrast, in the
treated group of hypertensive patients, the rela-
tive risk was reduced to 1.3 (95% CI, 0.3-3.9).
Recently, a retrospective analysis has been
published from Indiana.34 This was based on
centralized administrative data from 1900 Afri-
can Americans older than 65 years without
dementia at entry. They were followed up for a
period of 5 years while being treated with a
variety of 7 antihypertensive drugs. During that
period, 288 individuals (15%) developed overt
cognitive impairment. The use of antihyperten-
sive medications, overall, reduced the chance of
developing dementia by 38% (odds ratio, 0.62;
95% CI, 0.48-0.84).
Although this looks encouraging, a corres-
ponding analysis of reported BP measurements
was inconclusive. Moreover, none of the 7 anti-
hypertensive drug categories prescribed, when
evaluated separately, achieved significant reduc-
tions in odds ratios.
The above results of antihypertensive treat-
ment in reducing cognitive deterioration, al-
though relatively encouraging in their own
right, ought to be interpreted with skepticism
because of their lack of properly matched
control groups and valid comparative statistics.
Moreover, a precise relation between the anti-
hypertensive effects of different drug types and
the incidence rates of cognitive deterioration/
overt dementia cannot be established. There also
arise caveats regarding optimal levels of
achieved BPs, both systolic and diastolic, in
relation to aging, as witnessed by the follow-up
study by Skoog et al.18 In particular, a sharp
decline in diastolic pressure in the elderly may
well prove to be counterproductive, both
in systemic30 and cerebral hemodynamic
effects32,35,36 as well as white matter lesions.29
A recent study from Beer Sheva, Israel, offers
some further reasons for caution in that respect.37
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(mean age, 76.5 years) and related a range of
cognitive functions to 4 groups of patients:
untreated normotensive patients (n = 136; aver-
age BP, 122.6/72.6 mm Hg); successfully treated
(with CCBs or ACE inhibitors) hypertensive
patients (n = 74; BP, 126.8/74.5 mm Hg);
untreated hypertensive patients (n = 103; BP,
152/81 mm Hg); and treated but so-called
uncontrolled hypertensive patients (n = 172;
BP, 158.7/85.4 mm Hg). Rather unexpectedly,
the latter group scored best of all on the MMSE
scale and in the cognitive domains of long-term
memory and concentration. The CCBs exhibited
some additionally favorable action in this regard,
an aspect that will be dealt with later on.
The above results at first sight seem to deviate
from current ideas about optimal (maximal)
antihypertensive treatment. However, these find-
ings reinforce the relativism arising from quoted
above18,29,30,32,35,36 in that there may be a
potential hazard of bovercorrectingQ BPs in
subjects 70 years and older. One does not need
to be clairvoyant to realize that such utterly
bnormalizedQ BP values as reported in the Beer
Sheva study in elderly with long-standing hy-
pertension may well interfere with their (chron-
ically up-regulated) autoregulation of cerebral
vascular resistance. Chronic underperfusion of
the brain is quite likely to occur and thereby
accentuate the process of cognitive decline.22
Conversely, the provocative finding that non-
responders to treatment performed better than
untreated hypertensive patients is enigmatic and
open to speculation (whether selective cerebral
vasodilation or beneficial cerebrocellular
effects). We will return to the latter issue after
discussing the literature on prospective random-
ized trials.Fig 1. Syst-Eur phases 1 and 2. Systolic and diastolic
BPs in patients initially assigned to placebo or active
treatment. Results are separately given for 4695
patients randomized in the double-blind trial (left)
and for 3517 participants subsequently enrolled in the
open-label study (right). Reprinted with permission
from J Hypertens 2004;22:847-857.Results of Long-term, Prospective,
Randomized, Placebo-controlled
Trials
In this regard, no specific trials have been
conducted with a primary focus on prevention
of cognitive deterioration per se. This kind of
study had to be embedded in larger cardiovas-
cular end point–oriented trials, if only for the
obvious reason that mental disorientation cannot
be studied in a somatic vacuum.In the prospectively planned Medical Research
Council (MRC) trial of treatment in older patients
with hypertension,38 subjects were properly
randomized to a diuretic, b-blocker, or placebo.
Psychometric tests were performed, covering a
period of 54 months. In this substudy, no
significant differences in test scores were detected
between the actively treated groups and those
assigned to placebo. Although, it should be noted
that there were numerous subjects from the
placebo group crossing over to active treatment,
which unavoidably has confused the results with
regard to the bintention-to-treatQ analysis applied
to the above trial.
Although the above reviewed MRC study,38
despite elaborate psychometric assessments,
unfortunately did not report on the incidence
of overt dementia per se, other antihypertensive
trials in the elderly focused on the incidence of
dementia proper: Systolic Hypertension in the
Fig 2. Incidence of dementia in the Syst-Eur trial
(double-blind phase followed by open active treat-
ment phase (intention-to-treat mode of analysis).
Reprinted with permission from Arch Intern Med
2002;162:2046-2052.
Fig 3. Meta-analysis of randomized antihypertensive demen
Semin in Cerebrovasc Dis Stroke 2003;3:155-160.
BIRKENHA¨GER AND STAESSEN6Elderly Program,39,40 Perindopril Protection
against Recurrent Stroke Study,41 Study on
Cognition and Prognosis in the Elderly,42
Systolic Hypertension in Europe (Syst-Eur),43
and Syst-Eur 2.44
In the Systolic Hypertension in the Elderly
Program trial substudy on 2034 subjects,39 the
incidence of dementia after 5 years was similar:
in the placebo group, 1.9%, and in the group
receiving treatment with chlorthalidone as the
primary drug, 1.6%. However, according to a
later more detailed evaluation,40 a differential
dropout and loss of data from participants in the
placebo- and actively treated groups may well
have biased the analysis of cognitive effects of
active treatment and, hence, obscured a protec-
tive action of the antihypertensive regimen.
In the Perindopril Protection against Recur-
rent Stroke Study,41 the ACE inhibitor perindo-
pril failed to prevent poststroke dementia.
However, in combination with the diuretictia prevention studies. Reprinted with permission from
PROGRESS IN CARDIOVASCULAR DISEASE 7indapamide, a 23% reduction ( P = .05) in the
incidence of dementia was observed.
The Study on Cognition and Prognosis in the
Elderly42 tested the protective effect of the AT1-
blocker candesartan against placebo. As to the
latter group, it should be noted that 80% of
patients on bplaceboQ actually received a diuretic
for ethical reasons. Small wonder that this
procedure actually invalidated the trial results,
which failed to demonstrate any protective effect
of candesartan on dementia.
The Syst-Eur trial included a side project
investigating, in a double-blind fashion, the
incidence of dementia in 2418 subjects 60 years
and older with systolic hypertension.43 The basic
treatment consisted of the CCB nitrendipine vs
matching placebo as primary drug, with enalapril
and hydrochlorothiazide and their matched pla-
cebos as complementary medication when con-
sidered to be necessary. The median follow-up
lasted only 2 years because of a critical difference
between stroke rates in the actively and placebo-
treated groups. Active treatment reduced demen-
tia by 50% from 7.7 to 3.8 per 1000 observation
years in stroke-free subjects. After the close of the
double-blind period, it was decided, for ethical
reasons, to offer all patients, including those in
the former placebo group, the active form of trial
medication for an extended period.
This move, designated as Syst-Eur 2, doubled
the observation period in an open fashion.44 As
indicated in Fig 1, in the course of the
latter period, BPs approached identity in the
earlier placebo- and actively treated patients.45
Nevertheless, the latter, as indicated in Fig 2,
still exhibited a relative profit in avoiding or at
least retarding the development of dementia
(55%, P b .001).45
Altogether, the combination of the above 4
trials would seem to offer only a slim profit of
antihypertensive treatment for preventing de-
mentia: as indicated in Fig. 3, the overall odds
ratio was 0.89 (95% CI, 0.75-1.04).46 Exclusion
of drugs affecting the renin-angiotensin system
(perindopril without indapamide and candesar-
tan) would lead to a more promising pooled
odds ratio (0.75; 95% CI, 0.60-0.94).46 Despite
its small numbers, the double-blind phase of the
Syst-Eur trial,43 because of its primary drug
nitrendipine, apparently carried the best message
of preventing dementia (Fig 3).Discussion
Dementia (whether diagnosed as being vascular
or degenerative), because of increasing somatic
longevity of the elderly population, looms ahead
as an epidemic of catastrophic proportions. This
will occur in the aging population at large but
apparently even more so in hypertensive
patients. Although hypertensive target organ
damage, in general, may be attenuated through
adequate treatment with all currently available
antihypertensive drugs, cognitive deterioration
seems to be quite resistant to such routine
treatment, as indicated above. Our favorable
experience in the Syst-Eur trial, with a dihydro-
pyridine CCB as the primary drug, is tempting us
to recommend this class of antihypertensives for
the prevention of both types of overt dementia,
provided that the reduction in BP remains within
reasonable limits for this age group, as indicated
in Fig 1.
Some studies seemed to be at variance with our
findings, but both were retrospective and con-
founded by indication, in the sense that CCBs
were favored for high-risk patients.47,48 This is a
particularly disturbing feature of the interpreta-
tion of treatment results of CCBs.49
Several better-organized, prospective studies
(although not in a properly randomized, placebo-
controlled fashion), resulted in statistically sig-
nificant favorable effects of the dihydropyridine
CCB nimodipine on containing mental deteriora-
tion50 and borderline significant protection by
dihydropyridine CCBs as a drug class.51
From a conceptual point of view, this clinically
established capacity of dihydropyridine CCBs
would be quite plausible. First of all, according
to in vitro and in vivo experimental evidence,
intracellular free calcium accumulation plays a
dominant role in age-related deterioration of a
cascade of cerebrocellular functions, which are
critically involved in brain aging, sensitization to
neurotoxins, and cell death.52-56 Secondly, the
distribution of action of dihydropyridine CCBs
(nitrendipine and nicardipine) has been shown to
focus on areas in the rat brain corresponding to
the human target cerebral areas involved in the
development of dementias.57,58
Because the circle of evidence regarding the
efficacy of the dihydropyridine class of CCBs in
preventing/retarding the incidence of both types
of dementia has virtually been closed, one can
BIRKENHA¨GER AND STAESSEN8hardly forfeit the conclusion that such agents
should at least be an ingredient of any hyperten-
sive regimen for individuals older than 60 years
or, perhaps, even younger given recent findings.23
We have argued repeatedly that there remains
an urgent need for further long-term randomized
comparative trials in hypertensive patients
encompassing the current main classes of antihy-
pertensive drugs, tailored to equal BPs and fo-
cusing on exponents of cognition.14,59 The
recently published Anti-hypertensive and Lipid-
lowering Treatment to Prevent Heart Attack
Trial60 and Anglo-Scandinavian Cardiac Out-
comes Trial–Blood Pressure Lowering Arm61
trials could have fulfilled this purpose, if only
the organizers would have monitored equal BPs
more closely and included proper attention to the
course of cognitive aspects in relation to the
courses of BP.
This leaves investigators involved in clinical
hypertension with the moral duty to organize
still another comparative prospective treatment
trial including assessment of the cognitive status
as a necessary ingredient of end point evaluation.
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